Food and Drug Administration (FDA) has published final guidance delaying enforcement of certain Drug Supply Chain Security Act (DSCSA) requirements until November 27, 2024. The extension will give trading partners (drug and device manufacturers, wholesale distributors, dispensers, and repackagers) additional time to further “develop and refine appropriate systems and processes to conduct interoperable, electronic tracing at the package level, to achieve robust supply chain security under the DSCSA while helping ensure continued patient access to prescription drugs,” the agency said in the guidance. FDA does not intend to take action to enforce the requirements under Section 582(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act as long as the product is introduced in a transaction into commerce by the product’s manufacturer or repackager before November 27, 2024. The final guidance will not impact NABP’s plans for providing DSCSA education to its member boards and trading partners, nor will it impact the launch of Pulse by NABP™.